FDA Is Raising The Bar On Hepatitis C Approvals
Executive Summary
New revised draft guidance on HCV drug development recommends that interferon-free regimens, which have become the standard of care, be studied against a direct-acting antiviral comparator.
You may also be interested in...
Hepatitis C Drugs May Need Longer Follow-Up, US FDA Guidance Says
Final guidance on developing direct-acting antivirals for hepatitis C virus clarifies recommended trial population and trial design for combination drugs.
FDA Approval Of Gilead’s Sofosbuvir Shows Flexibility On HCV Combos
Pricing means an $84,000 cost of therapy for some HCV patients, but $168,000 for others. The nucleotide polymerase inhibitor will be dosed with ribavirin but eliminates interferon for patients with genotypes 2 and 3, making it the first all-oral therapeutic regimen.
Madrigal’s FDA Approval In MASH Ends Years Of Industry Frustration
As the first approved MASH (formerly NASH) therapy, nearly four years after initially anticipated, Madrigal gets the opportunity to establish a MASH marketplace with Rezdiffra (resmetirom).